Loading...
Aurigene developed a cost-effective LPPS (Liquid Phase Peptide Synthesis) route for a tetramer peptide by eliminating expensive RP-HPLC, ion exchange, and lyophilization steps while controlling racemization of unnatural basic amino acids through an orthogonal protection strategy and optimized coupling protocols. The commercially viable alternative route delivered >97% HPLC purity at multi-kilo scale, meeting all predefined specifications and driving significant cost savings for the customer.
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market
